Regulatory guidelines describe the use of estimands in designing and conducting clinical trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of a trial. An estimand is defined by four inter-related attributes: the population of interest, the variable (endpoint) of interest, the way intercurrent events are handled and the population level summary. A trial may employ multiple estimands to evaluate treatment effects from different perspectives in order to address different scientific questions. As estimands may be an unfamiliar concept for many clinicians treating diabetes, this paper reviews the estimand concept and uses the PIONEER 1 phase 3a clinical trial, which investigated the efficacy and safety of oral semaglutide vs placebo, as an example of the way in which estimands can be implemented and interpreted. In the PIONEER 1 trial, two estimands were employed for each efficacy endpoint and were labelled as: (a) the treatment policy estimand, used to assess the treatment effect regardless of use of rescue medication or discontinuation of trial product, and provides a broad perspective of the treatment effect in the population of patients with type 2 diabetes in clinical practice; and (b) the trial product estimand, used to assess the treatment effect if all patients had continued to use trial product for the planned duration of the trial without rescue medication, thereby providing information on the anticipated treatment effect of the medication. Both approaches are complementary to understanding the effect of the studied treatments.
inform clinical and regulatory decision making. Various types of treatment effects can be defined, and different stakeholders may have conflicting views on the relevance and applicability of the treatment effects described. Whenever results from clinical trials are published, it is crucial to accompany the results with a precise explanation of the way in which data that may have been impacted by intercurrent events, such as use of rescue medication or trial product discontinuation, are accounted for, and thus the way in which treatment effects have been estimated.
In 2008, the US Food and Drug Administration (FDA) issued a draft guideline that recommended the use of a last-observation carried forward (LOCF) approach, in which missing data are replaced with the last observed value for a patient who discontinued the trial or treatment. 1 The LOCF approach implicitly assumes that a patient with good short-term disease control who prematurely discontinues the trial or trial product would also have similarly good disease control in the longer term. 2 As this assumption is debatable in many settings, and because the LOCF approach may result in bias in favour of the tested therapy, 3 a 2010 National Research Council (NRC) report, commissioned by the FDA, subsequently recommended against use of LOCF as a primary approach to handle missing data unless scientifically justified. 2 Other methods to handle missing data have since been adopted, including multiple imputation approaches and the mixed model for repeated measures (MMRM), which are employed according to the type of treatment effect to be estimated. 4 In the past, the type of treatment effect to be estimated was often insufficiently described in trial protocols or publications, which could have led to ambiguity and difficulties in interpreting data or comparing results from other trials. Because of a need for greater clarity and transparency, the International Council for Harmonisation (ICH)
Steering Committee endorsed the ICH E9 (R1) concept paper in 2014 concerning this topic 5 and a draft addendum was made available for public consultation in 2017 6 by various regulatory agencies, including the European Medicines Agency (EMA) 7 and the FDA. 8 This draft addendum presents a "structured framework to link trial objectives to a suitable trial design and tools for estimation and hypothesis testing and introduces the concept of an estimand, translating the trial objective into a precise definition of the treatment effect that is to be estimated." 6 The estimand concept is not new but, until recently, estimands have not been explicitly defined in clinical trial protocols or in publications.
The PIONEER programme is a global, clinical development programme for a novel oral formulation of the glucagon-like peptide-1 iii. the way to handle intercurrent events, for example, the way to account for use of rescue medication or premature trial product discontinuation in addressing the scientific question of interest;
iv. population level summary, for example, the mean difference between treatment groups.
Previously, attributes i, ii and iv were clearly defined in clinical trial protocols. However, attribute iii, intercurrent events, described as "Events that occur after treatment initiation and either preclude observation of the variable or affect its interpretation," 6 was often not explicitly defined. Rather, intercurrent events were defined implicitly by specification of the statistical analyses. 11 Thus, the choices for collection of data and the statistical analyses indicated the scientific question of interest rather than using the scientific question to guide decisions concerning data collection and statistical analyses. The ICH E9 (R1) draft addendum emphasizes the importance of utilizing the framework in a sequential manner, such that the estimand determines the method of estimation, that is, the analysis. It is important when planning a new trial to consider all relevant intercurrent events and to be able to justify the strategy chosen to account for these. For example, the treatment policy strategy, in which a treatment effect is assessed regardless of intercurrent events, will often tend to minimize the difference in treatment effect between groups. It should also be taken into consideration whether it is justifiable to account for the intercurrent event of premature trial product discontinuation because of drug-related adverse events according to the hypothetical strategy, in which the estimated treatment effect assumes that patients continued using trial drug even if not tolerated.
A clear, precise description of the type of treatment effect The two anticipated intercurrent events were both accounted for by the treatment policy strategy as described in the draft ICH E9 (R1) addendum. 6 One implication for trial design and conduct when applying this estimand was that all patients were encouraged to continue participation in the trial and data were collected even after discontinuation of trial product. This contrasts with historical approaches in which data would not have been collected following trial product discontinuation. 2 This estimand may, therefore, be of interest to both regulatory authorities and clinicians. 
| STATISTICAL METHODS USED IN THE PIONEER 1 TRIAL
In the PIONEER 1 trial, confirmation of the efficacy of oral semaglutide on change in HbA1c and in body weight from baseline to Week 26 was based on a weighted Bonferroni closed-testing strategy, to control the overall type 1 error for the hypotheses evaluated by the treatment policy estimand. 9 The statistical analysis should be aligned to estimands of interest 6 and the following pre-specified analyses were used to estimate each of the estimands in the PIONEER 1 trial.
The treatment policy estimand was estimated by a pattern mixture model, using multiple imputation to handle missing data from Week 26 for both confirmatory endpoints (Figures 1 and 2) . Data collected at Week 26 from all randomized patients, irrespective of premature discontinuation of trial product and/or initiation of rescue medication, were included in the statistical analysis. Imputation was undertaken within groups, defined by trial product and treatment status at Week 26. The assumption is that the behaviour of patients who discontinued trial product or initiated rescue medication, but for whom data were missing at the primary evaluation time point, is best described by patients with the same treatment status for whom data were available at the primary evaluation time point. The treatment policy estimand used in the PIONEER 1 trial may provide a broad perspective of the treatment effect and the statistical approach relies on fewer assumptions than other statistical approaches. 6 Both imputation and analysis were based on analysis of covariance models.
Results were combined by use of Rubin's rule. 19 Recent US prescribing information for the subcutaneous GLP-1 receptor agonist semaglutide 20 reported results with an approach similar to that used in the PIONEER 1 trial to estimate the treatment policy estimand.
The trial product estimand was estimated using an MMRM that incorporated data from all randomized patients, collected prior to premature trial product discontinuation or initiation of rescue medication (Figures 1 and 2 ). The independent effects included in the model were treatment and region as categorical fixed effects and baseline value as a covariate, all nested within visit. An unstructured covariance matrix for endpoint measurements within the same patient was employed. 9 The MMRM is based on the assumption that data are missing at random, meaning that patients for whom data were missing would be considered to behave similarly to other patients in the same treatment group. The trial product estimand aims to provide information concerning the anticipated effect of trial product, but should not be considered equivalent to the per-protocol or complete case analysis. The MMRM analysis used to estimate the trial product estimand differs from a per-protocol or complete-case analysis because it includes data from all randomized patients, rather than a subset of the randomized patients. Recent EU prescribing information for the subcutaneous GLP-1 receptor agonist semaglutide 21 reported results with an approach similar to that used in the PIONEER 1 trial to estimate the trial product estimand.
| INTERPRETING RESULTS FROM ESTIMANDS INCORPORATED INTO THE PIONEER 1 TRIAL
In the PIONEER 1 trial, all dose levels of oral semaglutide were superior to placebo in reducing HbA1c and superior reductions in body weight were observed for the 14 mg dose compared with placebo ( Figure 2 ).
In the PIONEER 3 trial, compared with sitagliptin, the 7 mg and 14 mg doses of oral semaglutide resulted in superior reductions in HbA1c and body weight. 10 While the two estimands used in the PIONEER 1 and PIONEER 3 trials addressed two different scientific questions of interest, both contribute to the full clinical picture. As outlined earlier, the On-treatment with rescue medication Withdrawn
The bands represent the proportion of subjects by treatment status until the planned end-of-treatment visit F I G U R E 3 Frequency and timings of intercurrent events in the PIONEER 1 trial 9 results for both estimands are dependent on the frequency of intercurrent events and will be similar if these are very low. The PIONEER 1 trial had a very high completion rate (92% to 97%), and 85% to 87% of patients across the four treatment arms completed the trial and continued with trial product without use of rescue medication, 9 thus providing a high degree of concordance between the results of the two estimands. The frequency and timing of intercurrent events during the PIONEER 1 trial is illustrated in Figure 3 .
It is of interest to note the way in which handling of intercurrent events is reflected in the reported results. With the highest dose of oral semaglutide tested (14 mg), the estimated treatment difference in HbA1c, compared with placebo, as assessed by the trial product estimand (that is, the treatment effect if rescue medication had not been initiated and all patients remained on the trial product), was greater by 0.3% points than the estimated treatment effect according to the treatment policy estimand (that is, the treatment effect regardless of discontinuation of trial product or use of rescue medication) ( Figure 2 ). This was primarily the result of the greater reduction in HbA1c with placebo for the treatment policy estimand, which is probably a reflection of the increased use of rescue medication in the placebo group (14%) vs the oral semaglutide 14 mg group (1.1%).
9
Discontinuation of trial product occurred more frequently with oral semaglutide 14 mg compared with placebo ( Figure 3 ) and, as the majority did not switch to another glucose-lowering agent or may have switched to a less effective glucose-lowering agent, the inclusion of data after trial product discontinuation for the treatment policy estimand could also have contributed to the smaller treatment difference observed between oral semaglutide 14 mg and placebo. Likewise, with oral semaglutide 14 mg, the estimated treatment difference vs placebo for body weight was greater by 0.3 kg for the trial product estimand than for the treatment policy estimand (Figure 2 ), which may be because semaglutide has been shown to markedly reduce body weight compared with many other glucose-lowering agents [22] [23] [24] and, consequently, patients who discontinued trial product prematurely would not be expected to experience the same weight loss as those continuing the trial product.
| SUMMARY
The ICH E9 (R1) draft addendum provides a general framework to ensure alignment of trial planning, trial design, trial conduct, data anal- 
